Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma, Follicular 18Lymphoma 18Lymphoma, Mantle-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Lymphoma, Non-Hodgkin 9Recurrence 6Hodgkin Disease 6Waldenstrom Macroglobulinemia 5Neoplasms 3Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphatic Diseases 2Leukemia, Hairy Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Sezary Syndrome 1Proteostasis Deficiencies 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

Paclitaxel 72Bevacizumab 63Carboplatin 57pembrolizumab 47olaparib 33Gemcitabine 29Specimen Handling 27Cyclophosphamide 27liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 20Taxes 20Nivolumab 19Topotecan 18fludarabine 17Biopsy 17Doxorubicin 15Immunoglobulin G 13Disulfides 13Fulvestrant 12Oxaliplatin 11Blood Specimen Collection 11durvalumab 10Ipilimumab 10Fluorouracil 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Bendamustine Hydrochloride × 1 year × Clear all
NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡